CASRAI Dictionary

Tag: UKRI research integrity

  • UK Research Integrity Office vs US ORI: Comparing Oversight Models

    For institutions with staff, students, or funding on both sides of the Atlantic, understanding how research misconduct is handled is not an academic curiosity — it shapes compliance obligations, reporting duties, and reputational risk. The UK Research Integrity Office (UKRIO) and the US Office of Research Integrity (ORI) are the two most frequently cited reference points for research integrity oversight in the English-speaking research world, yet they sit at opposite ends of the regulatory spectrum: one advisory, one statutory. This analysis sets out what separates the UK’s Concordat-based, self-governing model from the US’s federally regulated assurance regime, and what that gap means in practice for institutions and publishers operating across both jurisdictions.

    Overview: two philosophies of oversight

    The UK has no statutory research-integrity regulator. Instead, oversight is distributed across independent charities, a voluntary sector-wide concordat, and each institution’s own governance. The US, by contrast, ties oversight of biomedical and behavioural research directly to federal funding: any institution receiving Public Health Service (PHS) money — chiefly through the National Institutes of Health (NIH) — must operate under enforceable federal regulation.

    This is the single most important distinction for anyone comparing the two systems: the UK model relies on reputational and contractual incentives to drive good practice, while the US model relies on funding-conditional legal compliance.

    The UK model: UKRIO, the Concordat, and self-governance

    UKRIO was established in 2006 as an independent charity. It offers confidential, impartial advice to researchers, institutions, and members of the public on good research conduct and on handling allegations of misconduct — but it does not investigate cases itself. That responsibility sits with the research organisation where the alleged conduct occurred, guided by UKRIO’s Code of Practice for Research.

    Sitting alongside UKRIO is the Concordat to Support Research Integrity, first published by Universities UK in 2012 and substantially revised in 2019. The Concordat is a voluntary framework, not legislation, built around five commitments:

    • Maintaining the highest standards of rigour and integrity in research
    • Conducting research in an appropriate, ethically sound, and legally compliant way
    • Supporting a research environment that is underpinned by a culture of integrity
    • Using robust and fair processes to investigate allegations of misconduct
    • Working openly and transparently, including public reporting on research integrity

    UK Research and Innovation (UKRI) and Research England are among the Concordat’s signatories, alongside the UK’s major research funders and universities. More recently, UKRI has moved to strengthen system-level coordination through a Committee on Research Integrity, intended to work alongside UKRIO on cross-sector oversight rather than to replace institutional responsibility — a signal that the advisory model is being reinforced rather than converted into a regulator.

    One point that is often glossed over: UKRIO’s Code of Practice defines misconduct more broadly than the classic fabrication-falsification-plagiarism (FFP) triad. It also covers matters such as proceeding without necessary ethical approval, misrepresenting data or authorship, and breaching a researcher’s duty of care — a wider net than the narrower legal definition used in the US.

    The US model: ORI and federal regulatory assurance

    The Office of Research Integrity sits within the US Department of Health and Human Services (HHS), under the Office of the Assistant Secretary for Health. Its jurisdiction is defined by federal regulation — 42 CFR Part 93 — and applies to institutions receiving PHS funding, which includes the large majority of federally funded biomedical and behavioural research in the United States.

    Unlike UKRIO, ORI operates within an assurance framework: institutions receiving PHS funds must file an institutional assurance confirming they have policies and procedures for handling misconduct allegations that meet federal standards. Institutions still conduct the initial investigation, but ORI reviews and can reopen or challenge that process. Where misconduct is confirmed, ORI can recommend administrative actions to HHS, ranging from supervision and certification requirements to debarment from federal funding — a consequence with no direct UK equivalent, since UKRIO has no power to withhold funding from anyone.

    Critically, the federal definition of research misconduct that ORI enforces is narrower than UKRIO’s: fabrication, falsification, and plagiarism (FFP) only, as set out in 42 CFR §93.103. Authorship disputes, data-management failures, or ethics-approval breaches that UKRIO would treat as misconduct concerns typically fall outside ORI’s formal jurisdiction, though they may still be handled under an institution’s own policies.

    Comparing the two models side by side

    Feature UK: UKRIO / Concordat US: Office of Research Integrity
    Legal status Independent charity; voluntary sector concordat Federal agency within HHS
    Established 2006 (UKRIO); 2012, revised 2019 (Concordat) 1992
    Governing basis No statute; reputational/contractual adoption Federal regulation, 42 CFR Part 93
    Investigatory role Advisory only; institutions investigate Reviews/oversees institutional investigations
    Misconduct definition Broader — includes ethics-approval and duty-of-care breaches Narrower — fabrication, falsification, plagiarism only
    Enforcement power None; promotes good practice via guidance Can recommend sanctions, including funding debarment
    Scope All disciplines, all UK research organisations PHS-funded biomedical/behavioural research
    Funding model Subscribing institutions pay for UKRIO’s services Federally funded as part of HHS budget

    Common questions on research integrity oversight

    What is the UK Research Integrity Office?

    The UK Research Integrity Office (UKRIO) is an independent charity, established in 2006, that provides expert advice and guidance on good research practice and the handling of misconduct allegations. It has no statutory or investigatory powers — responsibility for investigating allegations remains with individual research institutions.

    What does the US Office of Research Integrity do?

    The Office of Research Integrity (ORI) is a federal agency within the US Department of Health and Human Services. It oversees research-misconduct policy for Public Health Service-funded research, reviews institutional investigations, and can recommend administrative sanctions, including funding debarment.

    What counts as research misconduct under UKRIO’s Code of Practice?

    UKRIO’s Code of Practice for Research defines misconduct more broadly than fabrication, falsification and plagiarism alone, also covering breaches such as proceeding without ethical approval, misrepresenting data, and failing in a researcher’s duty of care — a wider net than the US federal definition.

    What are the core commitments of the Concordat to Support Research Integrity?

    The Concordat to Support Research Integrity, revised in 2019, sets out five commitments covering rigour and transparency, appropriate governance, a supportive research environment, robust misconduct investigation, and transparent public reporting — voluntarily adopted by UK universities and funders including UKRI.

    Implications for multinational institutions and publishers

    For institutions operating research programmes, joint ventures, or staff exchanges across the UK and US, the practical consequence of these two models is a compliance asymmetry. A collaboration that falls short of UKRIO’s broader Code-of-Practice standard may still be technically compliant with ORI’s narrower FFP definition, and vice versa — an ethics-approval lapse that UKRIO would flag as a misconduct concern may sit outside ORI’s formal jurisdiction entirely.

    • Research administrators managing joint UK-US grants should map both frameworks into a single institutional misconduct policy rather than defaulting to whichever funder’s rules are stricter on paper.
    • Publishers and journal editors handling cross-border authorship disputes should recognise that a “no finding” outcome from a US institution under ORI’s FFP standard does not necessarily mean the same conduct would clear UKRIO’s Code of Practice, or vice versa.
    • Funders operating in both jurisdictions benefit from Concordat-style transparent reporting commitments even where they are not legally required, since it narrows the gap with ORI’s assurance-based accountability.

    Outlook: converging pressures, diverging structures

    Neither system shows signs of formally converging. The UK’s 2019 Concordat revision and UKRI’s growing coordination role reinforce, rather than replace, the advisory model; the US assurance regime remains anchored in federal regulation that would require congressional or HHS rule-making to change materially. What is converging is expectation: international publishers, funders such as Horizon Europe, and bodies like COPE and the Committee on Publication Ethics increasingly expect institutions to demonstrate research-integrity governance regardless of which national model applies. For multinational institutions, the practical answer is not to wait for the UK and US to align, but to build internal policy that satisfies the stricter of the two standards on every point where they diverge.